VIPoma interventions: Difference between revisions
Jump to navigation
Jump to search
Homa Najafi (talk | contribs) (Created page with "__NOTOC__ {{VIPoma}} {{CMG}}{{AE}}{{Homa}} ==Overview== There are no recommended therapeutic interventions for the management of [disease name]. OR [Name of intervention] is...") |
m (Bot: Removing from Primary care) |
||
| (2 intermediate revisions by one other user not shown) | |||
| Line 3: | Line 3: | ||
{{CMG}}{{AE}}{{Homa}} | {{CMG}}{{AE}}{{Homa}} | ||
==Overview== | ==Overview== | ||
The mainstay of treatment for VIPoma is [[surgery]]. [[Hepatic artery]] [[embolization]] or transcatheter [[chemoembolization]] with [[doxorubicin]] or [[cisplatin]] is usually reserved for patients with [[liver]] [[metastases]]. Moreover, in [[patients]] with [[liver]] [[metastases]] less than 3 cm [[radiofrequency ablation]] and [[cryoablation]] can be used. | |||
==Indications== | |||
The mainstay of treatment for VIPoma is [[surgery]]. [[Hepatic artery]] [[embolization]] or transcatheter [[chemoembolization]] with [[doxorubicin]] or [[cisplatin]] is usually reserved for patients with [[liver]] [[metastases]]. Moreover, in [[patients]] with [[liver]] [[metastases]] less than 3 cm [[radiofrequency ablation]] and [[cryoablation]] can be used.<ref>{{Cite journal | |||
| author = [[Julie King]], [[Richard Quinn]], [[Derek M. Glenn]], [[Julia Janssen]], [[Denise Tong]], [[Winston Liaw]] & [[David L. Morris]] | |||
| title = Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases | |||
| journal = [[Cancer]] | |||
| volume = 113 | |||
| issue = 5 | |||
| pages = 921–929 | |||
| year = 2008 | |||
| month = September | |||
| doi = 10.1002/cncr.23685 | |||
| pmid = 18618495 | |||
}}</ref><ref name="MougLeen2006">{{cite journal|last1=Moug|first1=Susan J.|last2=Leen|first2=Edward|last3=Horgan|first3=Paul G.|last4=Imrie|first4=Clement W.|title=Radiofrequency Ablation Has a Valuable Therapeutic Role in Metastatic VIPoma|journal=Pancreatology|volume=6|issue=1-2|year=2006|pages=155–159|issn=14243903|doi=10.1159/000090257}}</ref> | |||
==References== | ==References== | ||
| Line 30: | Line 26: | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
[[Category:Medicine]] | [[Category:Medicine]] | ||
[[Category:Oncology]] | [[Category:Oncology]] | ||
[[Category:Up-To-Date]] | [[Category:Up-To-Date]] | ||
[[Category:Endocrinology]] | [[Category:Endocrinology]] | ||
[[Category:Gastroenterology]] | [[Category:Gastroenterology]] | ||
Latest revision as of 00:40, 30 July 2020
|
VIPoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
VIPoma interventions On the Web |
|
American Roentgen Ray Society Images of VIPoma interventions |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Homa Najafi, M.D.[2]
Overview
The mainstay of treatment for VIPoma is surgery. Hepatic artery embolization or transcatheter chemoembolization with doxorubicin or cisplatin is usually reserved for patients with liver metastases. Moreover, in patients with liver metastases less than 3 cm radiofrequency ablation and cryoablation can be used.
Indications
The mainstay of treatment for VIPoma is surgery. Hepatic artery embolization or transcatheter chemoembolization with doxorubicin or cisplatin is usually reserved for patients with liver metastases. Moreover, in patients with liver metastases less than 3 cm radiofrequency ablation and cryoablation can be used.[1][2]
References
- ↑ Julie King, Richard Quinn, Derek M. Glenn, Julia Janssen, Denise Tong, Winston Liaw & David L. Morris (2008). "Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases". Cancer. 113 (5): 921–929. doi:10.1002/cncr.23685. PMID 18618495. Unknown parameter
|month=ignored (help) - ↑ Moug, Susan J.; Leen, Edward; Horgan, Paul G.; Imrie, Clement W. (2006). "Radiofrequency Ablation Has a Valuable Therapeutic Role in Metastatic VIPoma". Pancreatology. 6 (1–2): 155–159. doi:10.1159/000090257. ISSN 1424-3903.